Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Diabetes News

Glycosmedia is dedicated to bringing free, non-promotional, editorially independent news to a global audience about developments in diabetes, and is primarily aimed at health professionals.


Diabetic Retinopathy as a Predictor of Angiographic Coronary Atherosclerosis Severity in Patients with Type 2 Diabetes Mellitus

May 10th 2022

The presence and degree of DR are independent predictors of severe coronary atherosclerosis. Therefore, when evaluating whether a patient with T2DM is at high risk for CAD, the DR degree should be taken into consideration (Metabolic Syndrome and Obesity)

Categories: Cardiovascular, News, Ophthalmology
Tags: atherosclerosis, retinopathy, Type 2 Diabetes

Categories: Cardiovascular, Ophthalmology
Tags: atherosclerosis, retinopathy, Type 2 Diabetes

Differential prognostic burden of cardiovascular disease and lower-limb amputation on the risk of all-cause death in people with long-standing type 1 diabetes

May 10th 2022

CVD and LLA conferred a similar burden regarding mortality in type 1 diabetes population. Our findings encourage a careful consideration of people with type 1 diabetes and LLA as usually recommended for those with CVD, in terms of management of risk factors, treatments and prevention (Cardiovascular Diabetology)

Categories: Cardiovascular, Monitoring, News
Tags: amputation, mortality, Type 1 Diabetes

Categories: Cardiovascular, Monitoring
Tags: amputation, mortality, Type 1 Diabetes

Prognostic significance of metabolomic biomarkers in patients with diabetes mellitus and coronary artery disease

May 8th 2022

In patients with comorbid DM and CAD, novel metabolomic biomarkers and metabolomics-based prediction models could be recruited to predict clinical outcomes and assess the complexity of CAD, thereby enabling the integration of personalized medicine into routine clinical practice (Cardiovascular Diabetology)

Categories: Cardiovascular, Monitoring, News
Tags: biomarkers, metabolomic

Categories: Cardiovascular, Monitoring
Tags: biomarkers, metabolomic

Duration of diabetes and the risk of major cardiovascular events in women and men: a prospective cohort study of UK Biobank participants

May 5th 2022

The increased risk of CVD associated with longer duration of diabetes is similar in women and men, and thus cannot explain the higher excess risk from diabetes in women in this study population (Diabetes Research and Clinical Practice)

Categories: Cardiovascular, News
Tags: gender

Categories: Cardiovascular
Tags: gender

Glucagon-like peptide-1 receptor agonist prescribing patterns in adolescents with type 2 diabetes

May 2nd 2022

The United States Food and Drug Administration (FDA) has approved two GLP-1RAs, liraglutide 1.8 mg/d and exenatide extended-release (ER), for T2D in youth aged 10 years or older.2 However, little is known about GLP-1RA prescribing patterns in youth. The objective of this retrospective chart review was to explore GLP-1RA prescribing practices for adolescents with T2D (Diabetes, Obesity and Metabolism)

Categories: Medication, News
Tags: exenatide, GLP-1RA, liraglutide, Type 2 Diabetes

Categories: Medication
Tags: exenatide, GLP-1RA, liraglutide, Type 2 Diabetes

Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial

May 1st 2022

The dapagliflozin-induced plasma volume contraction may contribute to the initial SBP reduction, while a reduction in SNS activity may contribute to the persistent SBP reduction (Cardiovascular Diabetology)

Categories: Hypertension, Medication, News
Tags: dapagliflozin, exenatide, Type 2 Diabetes

Categories: Hypertension, Medication
Tags: dapagliflozin, exenatide, Type 2 Diabetes

Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6

May 1st 2022

These findings indicate that the CV outcomes for semaglutide were similar regardless of baseline metformin use, which may also apply to all GLP-1RAs (Cardiovascular Diabetology)

Categories: Cardiovascular, Medication, News
Tags: GLP-1RA, PIONEER 6, semaglutide, SUSTAIN 6

Categories: Cardiovascular, Medication
Tags: GLP-1RA, PIONEER 6, semaglutide, SUSTAIN 6

Impact of Cotadutide drug on patients with type 2 diabetes mellitus: a systematic review and meta-analysis

May 1st 2022

Cotadutide is safe and effective in reducing plasma glucose levels, HbA1c and body weight in individuals with type 2 diabetes (BMC Endocrine Disorders)

Categories: Medication, News
Tags: cotadutide, Type 2 Diabetes

Categories: Medication
Tags: cotadutide, Type 2 Diabetes

Magnitude of Glycemic Improvement in Patients with Type 2 Diabetes Treated with Basal Insulin: Subgroup Analyses from the MOBILE Study

April 28th 2022

While the benefit of CGM on TIR among patients with type 2 diabetes treated with basal insulin is apparent across the range of baseline glycemic control, the greatest impact of CGM is in those with the worst baseline glycemic control, particularly among those with HbA1c ≥10% (Diabetes Technology & Therapeutics)

Categories: News, Treatment
Tags: CGM, insulin, Type 2 Diabetes

Categories: Treatment
Tags: CGM, insulin, Type 2 Diabetes

Reductions in HbA1c with Flash Glucose Monitoring Are Sustained for up to 24 Months: A Meta-Analysis of 75 Real-World Observational Studies

April 27th 2022

Meta-analysis of RWE confirms that using the FreeStyle Libre system is associated with significant reductions in HbA1c for adults with T1DM or with T2DM. Reductions are greater for people with higher baseline HbA1c and are sustained for 24 and 12 months in T1DM and TD2M respectively (Diabetes Therapy)

Categories: Monitoring, News
Tags: FreeStyle, HbA1c, Type 1 Diabetes, Type 2 Diabetes

Categories: Monitoring
Tags: FreeStyle, HbA1c, Type 1 Diabetes, Type 2 Diabetes

Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER

April 27th 2022

Global use of glucose-lowering medications with established cardiovascular benefits has increased over time but remains suboptimal, particularly in sub-groups most likely to benefit. Substantial country-level variability exists independent of patient factors, suggesting structural barriers may limit more widespread use of these medications (BMC Endocrine Disorders)

Categories: Medication, News
Tags: DISCOVER, GLP-1 receptor agonists, SGLT2 inhibitors, Type 2 Diabetes

Categories: Medication
Tags: DISCOVER, GLP-1 receptor agonists, SGLT2 inhibitors, Type 2 Diabetes

Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial

April 26th 2022

Once-weekly treatment with tirzepatide showed superior glycaemic control measured using CGM compared with insulin degludec in participants with type 2 diabetes on metformin, with or without a SGLT2 inhibitor. These new data provide additional evidence to the effect of tirzepatide and potential for achieving glycaemic targets without increase of hypoglycaemic risk compared with a basal insulin (The Lancet Diabetes & Endocrinology)

Categories: Medication, News
Tags: degludec, glycaemic control, SURPASS-3 CGM, tirzepatide, Type 2 Diabetes

Categories: Medication
Tags: degludec, glycaemic control, SURPASS-3 CGM, tirzepatide, Type 2 Diabetes

Biggest-ever philanthropic gift to diabetes research brings Type 1 cure closer

April 26th 2022

An incredible and unprecedented £50 million investment from the Steve Morgan Foundation, the partnership will fund game-changing type 1 diabetes research that will pave the way to the development of new treatments and a cure (Diabetes UK)

Categories: News, Research
Tags: Type 1 Diabetes

Categories: Research
Tags: Type 1 Diabetes

Does Hepatitis C Virus Treatment by Directly Acting Antivirals Obligate Shifting Patients with Type 2 Diabetes from Oral Hypoglycemic Drugs to Insulin Therapy?

April 26th 2022

Achievement of sustained virologic response using interferon free, directly acting antivirals-based regimen was associated with significantly lower HbA1c 12 weeks after the end of therapy. The type of treatment used for type 2 diabetes (oral drugs or insulin) did not affect improved glycemic control observed after achieving sustained virologic response (Metabolic Syndrome and Obesity)

Categories: Management, News, Treatment
Tags: Antivirals, Hepatitis C Virus, Type 2 Diabetes

Categories: Management, Treatment
Tags: Antivirals, Hepatitis C Virus, Type 2 Diabetes

Mechanism and application of exosomes in the wound healing process in diabetes mellitus

April 26th 2022

Most of the recent studies are still in the preclinical stage, and the relevant drugs have not been approved for use. In the future, more research are required to determine the scope of application of exosomes and determine the production routes for a large number of clinical uses. Further studies on exosomes may provide a way to treat diabetic wounds in the future (Diabetes Research and Clinical Practice)

Categories: News, Wound Care
Tags: exosomes

Categories: Wound Care
Tags: exosomes

The English National Health Service Diabetes Prevention Programme (NHS DPP): A scoping review of existing evidence

April 24th 2022

The evidence is accumulating on NHS DPP uptake and retention most, with emerging evidence on programme outcomes (such as weight loss and HbA1c). More evidence is warranted on stakeholder experience to decipher how to overcome low initial and long-term engagement reported by the current evidence base (Diabetic Medicine)

Categories: Audits, News
Tags: NHS DPP

Categories: Audits
Tags: NHS DPP

Latent Autoimmune Diabetes in Youth Shows Greater Autoimmunity than Latent Autoimmune Diabetes in Adults: Evidence from a Nationwide, Multicenter, Cross-sectional Study

April 22nd 2022

A high prevalence of LADY exists in youth with T2D phenotype. Latent autoimmune diabetes forms a continuous age-related spectrum from LADY to LADA, in which LADY shows greater autoimmunity (Pediatric Diabetes)

Categories: News, Paediatrics
Tags: autoimmunity, lada, Type 2 Diabetes

Categories: Paediatrics
Tags: autoimmunity, lada, Type 2 Diabetes

Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial

April 22nd 2022

The consistent benefits of dapagliflozin on kidney and cardiovascular outcomes across KDIGO risk categories indicate that dapagliflozin is efficacious and safe across a wide spectrum of kidney disease severity (Diabetologia)

Categories: Medication, Nephropathy, News
Tags: DAPA-CKD, dapagliflozin, KDIGO

Categories: Medication, Nephropathy
Tags: DAPA-CKD, dapagliflozin, KDIGO

Correlation between the accumulation of skin glycosylation end products and the development of type 2 diabetic peripheral neuropathy

April 21st 2022

The cumulative amount of skin AGEs can be used as the diagnostic index and the prediction and evaluation index of DPN severity. Moreover, the diabetic peripheral neuropathy risk score can predict the risk of DPN in patients with T2DM (BMC Endocrine Disorders)

Categories: Neuropathy, News
Tags: AGE, Type 2 Diabetes

Categories: Neuropathy
Tags: AGE, Type 2 Diabetes

Potential Gains in Life Expectancy Associated With Achieving Treatment Goals in US Adults With Type 2 Diabetes

April 20th 2022

These findings can be used by clinicians to motivate patients in achieving the recommended treatment goals and to help prioritize interventions and programs to improve diabetes care in the US (JAMA)

Categories: Management, News
Tags: Type 2 Diabetes

Categories: Management
Tags: Type 2 Diabetes
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 236
  • Next Page »

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Gold Sponsors

Novo NordiskAstraZenecaNapp DiabetesBoehringer Ingelheim

Silver Sponsors

About Ascensia Diabetes CareAbbott Diabetes CareWelsh Endocrinology and Diabetes Society (WEDS)

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

News Archive

calendar-iconNews Archive ››

Categories

  • Audits
  • Bariatric
  • Biochemistry
  • Cardiovascular
  • Devices
  • Diagnosis
  • Diet
  • Education
  • Epidemiology
  • Genetics
  • Gestational
  • Guidance
  • Guidelines
  • Hepatology
  • Hypertension
  • Immunology
  • Management
  • Media
  • Medication
  • Meetings
  • Monitoring
  • Nephrology
  • Neuropathy
  • Nephropathy
  • Obesity
  • Ophthalmology
  • Paediatrics
  • Pathology
  • Pharma
  • Pharmacology
  • Physiology
  • Podiatry
  • Prediabetes
  • Prevalence
  • Prevention
  • Psychological
  • Reports
  • Research
  • Screening
  • Sponsorship
  • Technology
  • Testing
  • Transplantation
  • Treatment
  • Wound Care

To see all articles associated with a category just click on the category name.

Popular Tags

ADA BMI canagliflozin CGM CKD closed-loop COVID-19 dapagliflozin DPP4 DPP4 inhibitors Empagliflozin exenatide GLP-1 RA GLP-1RA GLP1 glycaemic control HbA1c heart failure hyperglycemia hypoglycemia incretin insulin insulin pump Insulin resistance Ketoacidosis liraglutide metformin microvascular mortality NAFLD NICE pioglitazone retinopathy semaglutide SGLT2 inhibitors sitagliptin statin sulfonylureas Type 1 Diabetes Type 2 Diabetes

To see all articles associated with a tag just click on the tag name.

Complete list of Tags ››

Recent Book and Product Reviews

  • Oxford Handbook of Medical Ethics and Law
  • Textbook of Emergency Cardiology
  • Braunwald’s Heart Disease
  • Conn’s Current Therapy 2022

Recent Diabetes Updates

  • National Diabetes Audit.
  • Funding bids
  • Publication of Studies During 2016 – Type 2 Diabetes
  • “Attitudes to obesity” findings from the 2015 survey

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com


Website by Wired up Wales

Copyright © 2022 Glycosmedia Partnership